China approves Novartis' multiple sclerosis treatment Mayzent

New York Times

9 May 2020 - Chinese regulators have approved Novartis' Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug maker said in a statement on Saturday.

Other drugs approved by China's National Medical Products Administration to treat patients with multiple sclerosis include Novartis' Gilenya, Bayer's Betaferon and Sanofi's Aubagio.

Read New York Times article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , China